Tag: Concert Pharmaceuticals

January 28, 2020

Concert Pharmaceuticals Announces Pricing of Public Offering

Concert announced the pricing of a public offering of 4,752,420 shares of its common stock at an offering price of...
September 3, 2019

Concert Pharmaceuticals Reports Positive CTP-543 Results

Concert Pharmaceuticals (NASDAQ:CNCE) has announced topline results from its Phase 2 trial evaluating CTP-543 in patients with moderate-to-severe alopecia areata....